Satellos Bioscience: Promising Novel Treatment For Duchenne Muscular Dystrophy

2025-09-02 09:37:25 ET

Toronto-based Satellos Bioscience (MSCL.TSX, MSCLF.OTCQB) is a clinical-stage small molecule development company focused on restoring natural muscle repair and regeneration for degenerative muscle diseases.

Its proprietary discovery platform, MyoReGenX, identifies, classifies and confirms regenerative deficits in serious muscle diseases. The platform can recreate the specialized muscle stem cell niche in vitro, which enables Satellos to identify and confirm drug targets, and test drug candidates for their ability to restore muscle stem cell repair mechanisms that have been impaired by genetic mutations, disease or injury....

Read the full article on Seeking Alpha

For further details see: